RxDoctor Payments DataLook up a doctor →

Samir Elian, MD

Interventional Cardiology · Flint, MINPI 1548235369

Payments from drug & device makers

$32,373in general payments, 2019–2025

Across 413 payments — averaging $78.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$22K
  • Medtronic$4K
  • Novartis$1K
  • Merck$860
  • Philips North America LLC$740
  • Amgen$554
  • plus $3K from 34 others

What the payments were for

  • Travel & lodging$2,86625%
  • Food & beverage$8,27272%
  • Education$2903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,373 in reported general payments places this provider in the 65th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$443,541
Medicare patients
459
Services billed
3,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban466$428,975
EntrestoSacubitril/Valsartan316$366,601
XareltoRivaroxaban166$179,026
BrilintaTicagrelor53$41,383
Repatha SureclickEvolocumab37$28,875
Ranolazine ErRanolazine179$19,376
Repatha SyringeEvolocumab17$19,227
VerquvoVericiguat15$15,154
FarxigaDapagliflozin Propanediol11$13,812
Nebivolol Hcl239$13,585
Metoprolol Succinate762$12,412
Atorvastatin Calcium884$12,382
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine28$10,766
Isosorbide Mononitrate ErIsosorbide Mononitrate542$10,655
Repatha PushtronexEvolocumab11$10,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$281$428,975466 claims
NovartisEntresto$1,445$366,601316 claims
Johnson & JohnsonXarelto$233$179,026166 claims
AstraZenecaBrilinta, Farxiga$141$55,19464 claims
MerckVerquvo$860$15,15415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →